Literature DB >> 9925533

Therapeutic effects of benzoxazinorifamycin KRM-1648 administered alone or in combination with a half-sized secretory leukocyte protease inhibitor or the nonsteroidal anti-inflammatory drug diclofenac sodium against Mycobacterium avium complex infection in mice.

C Sano1, T Shimizu, K Sato, H Kawauchi, S Kawahara, H Tomioka.   

Abstract

The effects of half-sized secretory leukocyte protease inhibitor or diclofenac sodium administered alone or in combination with the benzoxazinorifamycin KRM-1648 on the therapeutic efficacy of KRM-1648 against Mycobacterium avium complex (MAC) in mice were studied. Neither of the two anti-inflammatory drugs affected the efficacy of KRM-1648, while they exerted significant modulating effects on tumor necrosis factor alpha production by MAC-infected macrophages.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 9925533      PMCID： PMC89078     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  32 in total

Review 1.  Potential problems in designing elastase inhibitors for therapy.

Authors:  J Travis; H Fritz
Journal:  Am Rev Respir Dis       Date:  1991-06

2.  The role of macrophages in host defence mechanisms against Mycobacterium avium complex infection induced in mice.

Authors:  H Saito; H Tomioka
Journal:  Res Microbiol       Date:  1990-02       Impact factor: 3.992

3.  T cell-dependent chronic neutrophilia during mycobacterial infections.

Authors:  R Appelberg; M T Silva
Journal:  Clin Exp Immunol       Date:  1989-12       Impact factor: 4.330

4.  Macrophage deactivating factor and transforming growth factors-beta 1 -beta 2 and -beta 3 inhibit induction of macrophage nitrogen oxide synthesis by IFN-gamma.

Authors:  A Ding; C F Nathan; J Graycar; R Derynck; D J Stuehr; S Srimal
Journal:  J Immunol       Date:  1990-08-01       Impact factor: 5.422

5.  Differing contribution of polymorphonuclear cells and macrophages to protection of mice against Listeria monocytogenes and Pseudomonas aeruginosa.

Authors:  K Tatsukawa; M Mitsuyama; K Takeya; K Nomoto
Journal:  J Gen Microbiol       Date:  1979-11

6.  The prostaglandin E1 analogue, misoprostol, regulates inflammatory cytokines and immune functions in vitro like the natural prostaglandins E1, E2 and E3.

Authors:  D R Haynes; M W Whitehouse; B Vernon-Roberts
Journal:  Immunology       Date:  1992-06       Impact factor: 7.397

7.  Capacity of Mycobacterium avium isolates to grow well or poorly in murine macrophages resides in their ability to induce secretion of tumor necrosis factor.

Authors:  S K Furney; P S Skinner; A D Roberts; R Appelberg; I M Orme
Journal:  Infect Immun       Date:  1992-10       Impact factor: 3.441

8.  In vitro cytokine release by activated murine peritoneal macrophages: role of prostaglandins in the differential regulation of tumor necrosis factor alpha, interleukin 1, and interleukin 6.

Authors:  J Marcinkiewicz
Journal:  Cytokine       Date:  1991-07       Impact factor: 3.861

Review 9.  Transforming growth factor beta (TGF-beta) in inflammation: a cause and a cure.

Authors:  S M Wahl
Journal:  J Clin Immunol       Date:  1992-03       Impact factor: 8.317

Review 10.  Interleukin-10.

Authors:  R de Waal Malefyt; H Yssel; M G Roncarolo; H Spits; J E de Vries
Journal:  Curr Opin Immunol       Date:  1992-06       Impact factor: 7.486
View more
  3 in total

1.  Effects of secretory leucocyte protease inhibitor on the production of the anti-inflammatory cytokines, IL-10 and transforming growth factor-beta (TGF-beta), by lipopolysaccharide-stimulated macrophages.

Authors:  C Sano; T Shimizu; K Sato; H Kawauchi; H Tomioka
Journal:  Clin Exp Immunol       Date:  2000-07       Impact factor: 4.330

Review 2.  The anti-inflammatory non-antibiotic helper compound diclofenac: an antibacterial drug target.

Authors:  K Mazumdar; S G Dastidar; J H Park; N K Dutta
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-04-28       Impact factor: 3.267

Review 3.  The New Frontier of Host-Directed Therapies for Mycobacterium avium Complex.

Authors:  Nathan P Crilly; Samuel K Ayeh; Petros C Karakousis
Journal:  Front Immunol       Date:  2021-01-22       Impact factor: 7.561
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.